Pharma

UK-US Trade Deal: What's in it for Pharma?

Despite the UK securing an initial trade agreement with the US, the pharmaceutical sector remains uncertain, as the deal notably omits specific provisions for medicines, leaving the industry awaiting clearer terms regarding potential tariffs and preferential treatment.

VYNE Therapeutics Faces Clinical Hold on VYN202 Program Following Toxicity Findings

VYNE Therapeutics has paused its Phase 1b trial of VYN202 for psoriasis after the FDA imposed a clinical hold due to testicular toxicity observed in non-clinical studies.

Ascletis Enters the Obesity Drug Spotlight with Bold Play on Oral GLP-1 Candidate

Ascletis advances oral GLP-1 drug ASC30 after Phase 1b shows strong weight loss and safety, shifting focus to obesity with a slower dose-escalation strategy.

Pfizer Halts Development of Oral GLP-1 Agonist Danuglipron Amid Liver Safety Signal

Pfizer halts once-daily oral GLP-1 program danuglipron after liver safety concerns, shifting focus to alternative obesity targets including a GIPR antagonist in Phase 2.

The Current and Future State of Personalised Medicine

How precision treatments, AI, and genomics are reshaping healthcare by using advanced technologies to deliver tailored treatments, early diagnoses, and better patient outcomes.

Novo Nordisk Announces Promising Results for CagriSema but Stocks Tell Different Story

REDEFINE 2 Phase 3 trial showed CagriSema led to a 15.7% weight loss in adults with obesity and type 2 diabetes, but the results fell short of expectations, causing a decline in the company's stock value.